Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Accurately determining a company’s long-term prospects isn’t easy, especially when sentiment is weak. That’s where StockStory comes in - to help you find attractive investment candidates backed by unbiased research. Keeping that in mind, here is one stock where Wall Street’s pessimism is creating a buying opportunity and two where the skepticism is well-placed.
Two Stocks to Sell:
Kulicke and Soffa (KLIC)
Consensus Price Target: $100 (-2.6% implied return)
Headquartered in Singapore, Kulicke & Soffa (NASDAQ: KLIC) is a provider of production equipment and tools used to assemble semiconductor devices
Why Are We Wary of KLIC?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 3.9% annually over the last five years
- Overall productivity fell over the last five years as its plummeting sales were accompanied by a decline in its operating margin
- Free cash flow margin shrank by 20.2 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
Kulicke and Soffa is trading at $102.67 per share, or 24.1x forward P/E. Dive into our free research report to see why there are better opportunities than KLIC.
Phibro Animal Health (PAHC)
Consensus Price Target: $51.20 (24.6% implied return)
With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.
Why Do We Think Twice About PAHC?
- Smaller revenue base of $1.5 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Estimated sales growth of 2% for the next 12 months implies demand will slow from its two-year trend
- Low free cash flow margin of 0.8% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
At $41.08 per share, Phibro Animal Health trades at 13.3x forward P/E. Read our free research report to see why you should think twice about including PAHC in your portfolio.
One Stock to Buy:
Bloom Energy (BE)
Consensus Price Target: $234.18 (-11.4% implied return)
Working in stealth mode for eight years, Bloom Energy (NYSE: BE) designs, manufactures, and markets solid oxide fuel cell systems for on-site power generation.
Why Are We Bullish on BE?
- Impressive 37.6% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Free cash flow profile has moved into positive territory over the last five years, indicating the company has passed a significant test
- Improving returns on capital suggest its past investments are beginning to deliver value
Bloom Energy’s stock price of $264.45 implies a valuation ratio of 115.9x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
